Sarah Cannon Research Institute | Strategic Alliance Partners

August 31, 2020

In a special episode of OncLive® On Air, Shiraj Sen, MD, PhD, and Roman Groisberg, MD, highlight research evaluating combination chemotherapy regimens in the evolving sarcoma treatment paradigm.

August 28, 2020

Denise A. Yardley, MD, highlights the evolving role of adjuvant CDK4/6 inhibition in HR-positive metastatic breast cancer.

August 27, 2020

Erika P. Hamilton, MD, discusses the pivotal data that led to the approvals of trastuzumab deruxtecan and tucatinib in metastatic HER2-positive breast cancer, factors considered in terms of treatment selection, and emerging agents under exploration.

August 21, 2020

Howard A. “Skip” Burris, III, MD, FASCO, FACP, discusses ​the utility of sacituzumab govitecan-hzi​y in metastatic triple-negative breast cancer.

August 19, 2020

Denise Yardley, MD, discusses challenges with ​resistance mechanisms in hormone receptor–positive, HER2-negative breast cancer. 

August 18, 2020

Erika P. Hamilton, MD, discusses updated data from the phase 2 HER2CLIMB trial examining tucatinib in patients with HER2-positive breast cancer and brain metastases.

August 18, 2020

Erika P. Hamilton, MD, discusses the efficacy of fam-trastuzumab deruxtecan-nxki in HER2-low breast cancer.

August 17, 2020

Denise Yardley, MD, discusses the role of endocrine therapy in combination with CDK4/6 inhibitors in patients with hormone receptor–positive, HER2-negative breast cancer and visceral metastases.

August 12, 2020

Howard A. “Skip” Burris, III, MD, FASCO, FACP, discusses immunotherapy, PARP inhibitors, and antibody-drug conjugates, which have become pillars of treatment in triple-negative breast cancer.

August 11, 2020

Howard A. “Skip” Burris, III, MD, FASCO, FACP, discusses ​treatment considerations in triple-negative breast cancer.

August 07, 2020

Howard A. “Skip” Burris, III, MD, FASCO, FACP, discusses using biomarkers to determine the benefits of immunotherapy and chemotherapy in triple-negative breast cancer.

August 07, 2020

David R. Spigel, MD, discusses the Fostering Excellence in Care and Outcomes in Patients with Stage III and IV NSCLC initiative, analyzes the survey data, and next steps for the research.

June 15, 2020

Jesus G. Berdeja, MD, discusses updated safety results from the ongoing phase 1b/2 CARTITUDE-1 trial (NCT03548207) with the CAR T-cell therapy JNJ-4528 in multiple myeloma.

June 15, 2020

Stephanie L. Graff, MD, discusses future research with immunotherapy in breast cancer.

June 09, 2020

Ian W. Flinn, MD, PhD, discusses the role of BTK inhibitors in chronic lymphocytic leukemia.

May 25, 2020

Howard A. "Skip" Burris, III, MD, FASCO, FACP, and Stephanie L. Graff, MD, discuss how the COVID-19 pandemic has affected cancer care, the collaborative efforts made between Sarah Cannon Research Institute and HCA to increase access to investigational COVID-19 treatments, and the steps ASCO has taken to ensure its members’ professional education and well-being during this time.

May 15, 2020

Therapeutic options for pretreated HER2-positive breast cancer now include tucatinib (Tukysa) as part of a triplet regimen with a tolerable safety profile that promises improved quality of life.

May 15, 2020

Therapeutic options for pretreated HER2-positive breast cancer now include tucatinib (Tukysa) as part of a triplet regimen with a tolerable safety profile that promises improved quality of life.

May 08, 2020

Erika P. Hamilton, MD, discusses the evolution of treatment in HER2-positive breast cancer.

April 22, 2020

Stephanie L. Graff, MD, director of the Breast Program at the Sarah Cannon Cancer Institute of HCA Midwest Health and associate director of the Breast Cancer Research Program at Sarah Cannon Research Institute, discusses the FDA approval of sacituzumab govitecan in metastatic triple-negative breast cancer (TNBC).